You are here

Case Report: Grade 3 mucositis in a patient under erlotinib treatment and radiotherapy

Presentation by Elika Loir at the TAO Congress on 19/20 November 2015

TAO15 - AERIO MEETS THE EXPERTS 05 ANG-HD

The patient, a 64-year-old woman who never smoked, is diagnosed with bronchial adenocarcinoma with EGFR mutation (Del19). The examination reveals hypercalcaemia, multiple bone lesions as well as a C3 lesion with recession of the posterior wall and epiduritis. She has a history of Sharp’s syndrome (mixed connective tissue disease) and takes hydroxychloroquine and prednisone.

The first-line treatment for the adenocarcinoma consists of erlotinib and biphosphonates, which the patient tolerates well. In addition, radiotherapy is started on day 30. By day 45, radiotherapy is stopped because the patient has developed grade 2 mucositis. Nevertheless, the mucositis worsens to grade 3 by day 55. After the presentation, the expert panel discusses the development of mucositis under erlotinib treatment and radiotherapy.

This case report is part of the programme “AERIO meets the experts” by the French Association of Residents in Oncology (AERIO) in collaboration with an expert panel (Dr. Mario Dicato, Luxembourg Medical Center, Luxembourg; Dr. Richard Gralla, A. Einstein School of Medicine, New York, USA; Dr. Jeffrey Crawford, Duke Cancer Center, Durham, USA; Dr. Pere Gascon, Hospital Clinic, Barcelona).


Elika Loir


Search this site

Stay up-to-date with our monthly e-alert

If you want to regularly receive information on what is happening in Quality of Life in Oncology research sign up to our e-alert.

Subscribe »

QOL (Quality of Life) newsletter e-alert

NEW! Free access to the digital version of a new publication in Cancer Supportive Care


Cancer cachexia: mechanisms and progress in treatment

Authors: Egidio Del Fabbro, Kenneth Fearon, Florian Strasser

This book was supported by an educational grant from Helsinn Healthcare SA.

Featured videos

Quality of Life promotional video

Made possible by an educational grant from Helsinn

Helsinn does not have any influence on the content and all items are subject to independent peer and editorial review

Society Partners

European Cancer Organisation Logo

Share